Condition: Solid Tumor · Biliary Tract Cancer · Head and Neck Squamous Cell Carcinoma · Sponsor: TiumBio Co., Ltd.
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
TiumBio Global http://www.tiumbio.com/en/ · 82-31-600-1500 · nce401_tu2218@tiumbio.com
Always discuss trial participation with your own doctor first.
| NEXT Oncology | San Antonio, Texas, United States | Active Not Recruiting |
| Hope Cancer Center | Tyler, Texas, United States | Active Not Recruiting |
| Medical Oncology | Spokane, Washington, United States | Active Not Recruiting |
| CHA University Bundang Medical Center | Seongnam, South Korea | Recruiting |
| Seoul National University Bundang Hospital | Seongnam, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| The Catholic University of Korea Seoul St. Mary Hospital | Seoul, South Korea | Recruiting |
| The Catholic University of Korea St. Vincent's Hospital | Suwon, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05784688